Brigitte Autran, Université de Pierre & Marie Curie, Paris,  France - Biosketch

Chair, Panel Discussion Session 3 : The role of new technologies in predicting efficacy and safety of new adjuvants and adjuvanted vaccines

Max Bastian, Paul-Ehrlich-Institut, Langen, Germany - Biosketch

Presentation Title: Bovine neonatal pancytopenia – Possible role of the adjuvant in a vaccine-induced fetal disease

Steve Black, University of Cincinnati, Ohio, USA - Biosketch

Chair, Session 1:  What has been learned from recent experience

Flora Castellino, Novartis, Sienna, Italy - Biosketch

Presentation Title: Characterization of functional T-cells able to provide help for production of protective antibodies

Bernard Charley, INRA, Jouy-en-Josas, France - Biosketch

Presentation Title: Lessons from the veterinary field

Behazine Combadière, Université Pierre & Marie Curie, Paris, France - Biosketch

Giuseppe Del Giudice, Novartis, Sienna, Italy - Biosketch

Chair, Session 3: The role of new technologies in predicting efficacy and safety of new adjuvants & adjuvanted vaccines

Arnaud Didierlaurent, GlaxoSmithKline Biologicals, Rixensart, Belgium - Biosketch

Presentation Title: Adjuvant studies in humans: Comparison of GSK adjuvant systems

Wendy Fantl, Stanford University, Palo Alto, USA - Biosketch

Presentation Title: Multidimensional Proteomic Single Cell Profiling by Mass Cytometry

Marie-Joëlle Frachette, Sanofi Pasteur, Lyon, France - Biosketch

Chair, Session 2: What can be learned from animal models? What are their limitations? Can they be replaced by in vitro models? Can in vitro models fill the gap?

Joe Francica, VRC / NIH, Bethesda, Maryland, USA - Biosketch

Presentation Title:  Adjuvant studies in non-human primates (NHP)

Martin Friede, WHO, Geneva, Switzerland - Biosketch

Chair, Session 2: What can be learned from animal models? What are their limitations? Can they be replaced by in vitro models? Can in vitro models fill the gap?

Bernard Fritzell, co-Chair, Human Vaccine Committee, IABS - Biosketch

Introduction – Scope of meeting

Nathalie Garçon, GlaxoSmithKline Biologicals, Rixensart, Belgium - Biosketch

Chair, Session 1: What has been learned from recent experience

Hana Golding, CBER / FDA, Bethesda, Maryland, USA - Biosketch

Chair, Session IV: Regulatory challenges related to the licensure of adjuvanted vaccines

Marion Gruber, FDA, USA - Biosketch

Presentation Title: Current FDA policies related to adjuvanted vaccines

Surender Khurana, CBER / FDA, Bethesda, Maryland, USA - Biosketch

Presentation Title:  Adjuvants, B cell epitope repertoire and antibody avidity

David Lewis, University of Surrey, United Kingdom - Biosketch

Chair, Panel Discussion, Session 2: What can be learned from animal models? What are their limitations? Can they be replaced by in vitro models? Can in vitro models fill the gap?

Arnaud Marchant, Université Libre de Bruxelle, Belgium - Biosketch

Gary Nabel, CVR / NIH, Bethesda, Maryland, USA - Biosketch

Presentation Title: B cell repertoire and vaccination

Helder Nayaka, Emory University, Atlanta, Georgia, USA - Biosketch

Presentation Title: Systems biology to predict immunogenicity and safety of adjuvants

Pieter Neels, EMA, United Kingdom - Biosketch

Chair, Session IV: Regulatory challenges related to the licensure of adjuvanted vaccines

Gerlinde Obermoser, Baylor Institute for Immunology Research, Dallas, Texas, USA - Biosketch

Presentation Title: Systems biology to evaluate innate and acquired immunity after administration of vaccine / adjuvanted vaccine

Marc Pallardy, Faculté de Pharmacie Paris-Sud, France - Biosketch

Presentation Title: Current guidelines for pre-clinical evaluation, with focus on the gaps and difficulties in their application: a review

John Petricciani, President, IABS - Biosketch

Opening address

Marina Zaitseva, CBER / FDA, Bethesda, Maryland, USA - Biosketch

Presentation Title: In vitro assays and pre-clinical models to predict safety/reactogenicity in humans: the current state of the art